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Abstract
Purpose Androgen receptor (AR) expression occurs in up to 86% of human epidermal growth factor receptor 2-positive 
(HER2+) breast cancers. In vitro, AR inhibitors enhance antitumor activity of trastuzumab, an anti-HER2 antibody, in tras-
tuzumab-resistant HER2+ cell lines. This open-label, single-arm, phase II study evaluated the efficacy and safety of enzalu-
tamide, an AR-signaling inhibitor, in patients with advanced HER2+ AR+ breast cancer previously treated with trastuzumab.
Methods Eligible patients had measurable or non-measurable evaluable disease per Response Evaluation Criteria in Solid 
Tumors (RECIST) v1.1, Eastern Cooperative Oncology Group status ≤ 1, no history of brain metastases, and previously 
received ≥ 1 anti-HER2 regimen for advanced disease. Patients received 160 mg oral enzalutamide daily and 6 mg/kg intra-
venous trastuzumab every 21 days until disease progression or unacceptable toxicity. Primary end point was clinical benefit 
rate at 24 weeks (CBR24); secondary end points included progression-free survival (PFS) and safety.
Results Overall, 103 women were enrolled [median age 60 years (range 34–83)]; 62% had received ≥ 3 lines of prior anti-
HER2 therapy. CBR24, comprising patients with confirmed partial responses (5%) and durable stable disease at 24 weeks 
(19%), was 24% in the efficacy evaluable set (n = 89). CBR24 did not seem related to AR-expression levels or hormone 
receptor status. Median PFS was 3.4 months (95% confidence interval 2.0–3.8). Overall, 97 (94%) patients experienced 
treatment-emergent adverse events (TEAEs), with fatigue most common (34%). Dyspnea (4%) and malignant neoplasm 
progression (3%) were the only TEAEs grade ≥ 3 reported in ≥ 3 patients. 22 patients (21%) reported serious TEAEs. Four 
patients (4%) experienced fatal, non-drug-related TEAEs.
Conclusions Enzalutamide plus trastuzumab was well tolerated, and a subset of patients in this heavily pretreated popula-
tion had durable disease control. Determination of biomarkers is needed to identify patients most likely to benefit from this 
combination.
ClinicalTrials.gov number NCT02091960
Keywords Androgen receptor · Enzalutamide · HER2 · Human epidermal growth factor receptor 2 · Metastatic breast 
cancer · Trastuzumab
Abbreviations
AE  Adverse event
AR  Androgen receptor
AR+  Androgen receptor-positive
BMI  Body mass index
BORR  Best overall response rate
CBR24  Clinical benefit rate at 24 weeks
CI  Confidence interval
CR  Complete response
ECOG  Eastern Cooperative Oncology Group
EES  Efficacy evaluable set
ER  Estrogen receptor
FAS  Full analysis set
FISH  Fluorescence in situ hybridization
HER2  Human epidermal growth factor receptor 2
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HER2+  Human epidermal growth factor receptor 
2-positive
HR  Hormone receptor
MBC  Metastatic breast cancer
NA  Data not available
NCI CTCAE  National Cancer Institute Common Termi-
nology Criteria for Adverse Events
ORR  Overall response rate
PFS  Progression-free survival
PgR  Progesterone receptor
PR  Partial response
RECIST  Response Evaluation Criteria in Solid 
Tumors
SAF  Safety analysis set
SD  Stable disease
T-DM1  Trastuzumab emtansine
TEAE  Treatment-emergent adverse event
TTP  Time to progression
TTR  Time to response
Introduction
Breast cancer is among the most frequently diagnosed 
malignancies and the second most common cause of cancer 
deaths in women worldwide, with an estimated 1.67 million 
new cases diagnosed globally in 2012 [1]. Breast cancer, 
including metastatic breast cancer (MBC), is a heterogene-
ous disease, making its prognosis and management complex. 
While the 5-year relative survival rate is 99% for patients 
presenting with localized disease, it is only 27% for patients 
with MBC [2]. Human epidermal growth factor receptor 2 
(HER2) is amplified/overexpressed in approximately 15% of 
all breast cancer cases [3], making treatment recommenda-
tions for MBC highly dependent on hormone receptor (HR) 
and HER2 status [3, 4]. Survival for patients with HER2-
positive (HER2+) MBC has been significantly prolonged 
due to anti-HER2 therapies [5–9].
The recommended first-line treatment for HER2+ MBC is 
chemotherapy plus dual HER2 inhibition with trastuzumab 
and pertuzumab [3, 4]. Trastuzumab emtansine (T-DM1) is 
recommended over lapatinib plus capecitabine as standard 
second-line therapy after trastuzumab-based first-line treat-
ment [4]. In practice, the anti-HER2 agent selected depends 
on country-specific availability, previous anti-HER2 therapy, 
and time to relapse [4, 10]. However, even with full access to 
anti-HER2 agents, the vast majority of patients will eventu-
ally experience disease progression. Thus, there remains an 
unmet medical need in HER2+ MBC treatment for effective 
new therapies [3, 4].
Androgen receptor (AR) expression is observed in up to 
86% of HER2+ breast cancers [11–13] and has been inves-
tigated as a potential therapeutic target in breast cancer. The 
AR-signaling inhibitor enzalutamide [14] is either approved 
or under regulatory consideration for approval for castra-
tion-resistant prostate cancer, irrespective of the presence 
of metastases, and metastatic castration-sensitive prostate 
cancer (also known as metastatic hormone-sensitive prostate 
cancer) around the world [15–17]. Enzalutamide enhances 
the in vitro antitumor activity of trastuzumab in trastu-
zumab-resistant HER2+ cell lines [18], warranting clinical 
investigation of whether inhibiting AR in HER2+ breast 
cancers in combination with currently available anti-HER2 
therapeutics could improve patient outcomes. We therefore 
evaluated the efficacy and safety of combining the anti-
HER2 therapy trastuzumab with enzalutamide in patients 
with HER2+ AR+ locally advanced breast cancer or MBC.
Patients and methods
Study design
This was a multinational, multicenter, open-label, single-
arm, two-stage, phase II trial evaluating the efficacy, safety, 
and tolerability of enzalutamide in combination with tras-
tuzumab (NCT02091960). The study was approved by an 
independent ethics review board at each participating site 
or by national authorities and was conducted according to 
the provisions of the Declaration of Helsinki and the Good 
Clinical Practice Guidelines of the International Council for 
Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use.
Study population
Eligible patients were women aged ≥ 18 years with histologi-
cally or cytologically proven HER2+ AR+ breast carcinoma 
(see Online Resource 1: Patients and methods). Inclusion 
in the study could be based on local or central pathology 
assessment. Patients with locally assessed breast cancer 
also had their samples sent for central pathology laboratory 
assessment. Patients were allowed to remain in the study 
if subsequent central assessment did not confirm locally 
assessed AR+ breast carcinoma.
Inclusion criteria of the study included the following: 
(i) metastatic or locally advanced disease that was not 
amenable to curative treatment and had to have measur-
able or non-measurable, evaluable disease per Response 
Evaluation Criteria in Solid Tumors (RECIST) v1.1 [19], 
(ii) previous treatment with ≥ 1 line of anti-HER2 therapy 
in the metastatic or locally advanced disease setting, (iii) 
documented progression or discontinued the most recent 
anti-HER2 therapy due to investigator decision or toxicity 
other than cardiotoxicity, and (iv) an Eastern Cooperative 
Oncology Group performance status ≤ 1 and a minimum life 
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expectancy of ≥ 6 months. Exclusion criteria included (i) 
severe concurrent disease, (ii) severe infection or significant 
comorbidity, (iii) known or suspected brain metastases or 
active leptomeningeal disease, (iv) a history of a non-breast-
cancer malignancy, (v) inadequate marrow, hepatic, and/or 
renal function, (vi) a history of seizures, and (vii) clinically 
significant cardiovascular disease.
Analysis sets
The safety analysis set (SAF) included all enrolled patients 
who received at least one or a partial dose of study treat-
ment. The full analysis set (FAS) was defined as all patients 
in the SAF who had centrally assessed AR+ breast cancer 
(defined as ≥ 10% of tumor cells with nuclear expression). 
The efficacy evaluable set (EES) included all patients in 
the FAS who had at least one available post-baseline tumor 
assessment. The primary analysis was performed in the EES, 
while all efficacy analyses were performed in both the EES 
and FAS. Patient disposition and safety were based on SAF.
Treatments
Patients received a once-daily oral dose of 160 mg enzalu-
tamide (4 × 40 mg capsules) and trastuzumab, starting with 
a loading dose (8 mg/kg) followed by either intravenous 
(6 mg/kg) or subcutaneous (600 mg/5 mL) administration 
every 21 days. Dose interruptions or modifications of enza-
lutamide and trastuzumab were permitted due to toxicity, 
as defined in the study protocol (see Online Resource 1: 
Patients and methods). Patients continued on treatment until 
disease progression, unacceptable toxicity, or any other dis-
continuation criteria were met.
Study end points
Primary end point was clinical benefit rate at 24 weeks 
(CBR24), defined as the proportion of evaluable patients 
with best objective response of confirmed complete response 
(CR) or partial response (PR) per RECIST v1.1 or prolonged 
stable disease (SD) ≥ 24 weeks. Key secondary end points 
were best overall response rate (BORR; CR or PR), overall 
response rate (ORR; CR or PR) at 24 weeks, progression-
free survival (PFS), time to progression (TTP), time to 
response (TTR), and safety. Prespecified exploratory end 
points included CBR24 in subgroups by AR-expression lev-
els, hormone receptor (HR) status, and lines of prior therapy.
Assessments
Radiographic disease assessments according to RECIST 
v1.1 [19] were performed by the investigator at baseline and 
every 8 weeks up to week 49, then every 12 weeks thereafter. 
Local AR testing results were confirmed centrally using the 
Ventana Assay (Ventana Medical Systems, Inc., Tucson, 
USA) (see Online Resource 1: Patients and methods). Safety 
assessments throughout the study included the recording 
of adverse events (AEs). Cardiac safety assessments were 
required throughout the study to monitor for trastuzumab-
associated cardiotoxicity (see Online Resource 1: Patients 
and methods).
Statistical analysis
The study followed an optimal Simon’s two-stage design to 
determine sample sizes. A CBR24 of ≥ 3 out of 21 evaluable 
patients was required in stage I to continue to stage II. In 
total, approximately 80 patients were planned to be enrolled 
to achieve a dataset with at least 66 evaluable AR+ patients. 
The null hypothesis that the true CBR24 is ≤ 10% was tested 
against a one-sided alternative at a 5% significance level. 
This design has a statistical power of 90% when the true 
CBR24 is 25%. Patients in the FAS were included in primary 
and secondary efficacy analyses. See Online Resource 2: 
Statistical analysis for descriptive statistics. CBR, BORR, 
and ORR are summarized, including 95% two-sided exact 
confidence intervals (CIs) (Clopper–Pearson method). 
Kaplan–Meier analyses were used to estimate the median 
PFS, TTP, and TTR.
Results
This trial was conducted in 35 centers in six countries 
(Belgium, Canada, Italy, Spain, United Kingdom, and 
United States). Between September 2014 and August 
2016, 103 patients were enrolled and received at least 
one dose of enzalutamide and trastuzumab (see Online 
Resource 3: Fig. S1). The actual enrollment was greater 
than the planned enrollment goal of 80 patients due to 
increased screening and patient recruitment. At the end 
of stage I, six out of 22 evaluable patients (27%; 95% 
CI 10.7–50.2) demonstrated CBR24, thus meeting the 
prespecified requirement for the study to continue to 
stage II.
Baseline patient demographics and disease characteristics 
are reported in Table 1. In the efficacy evaluable set, approx-
imately 52% of patients were HR + and 87% were perimeno-
pausal or post menopausal. All patients had been previously 
treated with trastuzumab, and 62% had received ≥ 3 lines of 
prior anti-HER2 therapy. HER2 status was locally deter-
mined. Local AR testing results were confirmed centrally 
using the Ventana Assay, with a concordance level of 98.6% 
(see Online Resource 4: Table S1). AR staining was high 
(i.e., 50–100% positive cells) in approximately 90% of 
patients.
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Table 1  Patient demographics 
and baseline characteristics
Safety analysis  seta 
(n = 103)
Full analysis  setb
(n = 96)
Efficacy evalu-
able  setc (n = 89)
Age (years)
 Median (range) 60.0 (34–83) 60.0 (34–83) 60.0 (34–83)
Age categories (years), n (%)
  ≤ 65 78 (76) 73 (76) 66 (74)
 66–75 18 (18) 17 (18) 17 (19)
 > 75 7 (7) 6 (6) 6 (7)
BMI (kg/m2)
 Median (range) 25.7 (14–50) 25.7 (14–50) 25.6 (14–50)
Ethnicity, n (%)
 Not Hispanic or Latino 98 (95) 91 (95) 84 (94)
 Hispanic or Latino 5 (5) 5 (5) 5 (6)
Race, n (%)
 White 90 (87) 83 (87) 78 (88)
 Black or African-American 8 (8) 8 (8) 6 (7)
 Asian 3 (3) 3 (3) 3 (3)
 Other 2 (2) 2 (2) 2 (2)
ECOG performance status at baseline, n (%)
 0 51 (49) 49 (51) 47 (53)
 1 51 (49) 46 (48) 42 (47)
 Unknown 1 (1) 1 (1) 0
Time from initial diagnosis to enrollment (days)
 n 95 89 83
 Median; minimum, maximum 1199; 30, 4713 1321; 30, 4713 1340; 30, 4713
HER2 status, n (%)d
 Positive 89 (86) 83 (86) 77 (87)
 Negative 2 (2) 2 (2) 2 (2)
 Unknown 12 (12) 11 (12) 10 (11)
HER2 testing method confirming HER2 status, n (%)d
 Immunohistochemistry 35 (34) 33 (34) 30 (34)
 In situ hybridization 27 (26) 25 (26) 24 (27)
 HER2 amplification 22 (21) 21 (22) 19 (21)
 Unknown 19 (18) 17 (18) 16 (18)
HR status, n (%)
 Positivee 51 (49) 48 (50) 46 (52)
 Negative 38 (37) 35 (36) 31 (35)
 Unknown 14 (14) 13 (14) 12 (14)
AR + from Ventana Assay, n (%)
  > 0– < 10% 2 (2) 0 0
 10– < 50% 8 (8) 8 (8) 7 (8)
 50–100% 88 (90) 88 (92) 82 (92)
 Unknown 5 0 0
Lines of prior antineoplastic therapy, n (%)f
 1 14 (13) 13 (14) 13 (15)
 2 20 (19) 17 (18) 15 (17)
 3 11 (11) 10 (10) 10 (11)
 4 12 (12) 12 (12) 11 (12)
  > 4 46 (45) 44 (46) 40 (45)
Lines of prior anti-HER2 therapy, n (%)
 1–2 NA NA 33 (37)
 3–4 NA NA 24 (27)
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The median duration of exposure for enzalutamide 
was 70 days (range 1–660). Patients received a median 
of four  trastuzumab infusions (see Online Resource 5: 
Table S2). At the time of data cut-off (February 2017), 12 
(12%) patients remained on treatment.
AR androgen receptor, BMI body mass index, ECOG Eastern Cooperative Oncology Group, ER estrogen 
receptor, FISH fluorescence in  situ hybridization, HER2 human epidermal growth factor receptor 2, HR 
hormone receptor, NA data not available, PgR progesterone receptor
a All enrolled patients who received at least one or a partial dose of study treatment
b All patients in the safety analysis set who had centrally assessed AR+ breast cancer (defined as ≥ 10% of 
tumor cells with nuclear expression)
c All patients in the full analysis set who had at least one available post-baseline tumor assessment
d Local HER2 testing method from most recent biopsy (all patients had at least one biopsy with HER2+ sta-
tus)
e Positive HR status = ER+ and PgR+ or ER− and PgR+ or ER+ and PgR−
f Includes all therapies in the settings of locally advanced and metastatic disease and recurrence. It excludes 
adjuvant and neoadjuvant therapy
g Post-menopausal status was defined as no spontaneous menses for ≥ 12 months with FISH > 40 IU/L for 
patients aged < 55 years, documented surgically sterile, or ≥ 1 month post hysterectomy prior to screening
Table 1  (continued) Safety analysis  seta 
(n = 103)
Full analysis  setb
(n = 96)
Efficacy evalu-
able  setc (n = 89)
  ≥ 5 NA NA 31 (35)
Menopausal status,g n (%)
 Premenopausal 13 (12) 12 (12) 12 (13)
 Perimenopausal 13 (12) 12 (12) 12 (13)
 Post menopausal 77 (76) 72 (76) 65 (74)
Table 2  Tumor response
CBR24 clinical benefit rate at 24  weeks, CI confidence interval, CR complete response, FAS full analysis set, PR partial response, RECIST 
Response Evaluation Criteria in Solid Tumors, SD stable disease
a Primary efficacy analysis set
b Best overall response per RECIST v1.1 (CR, PR, SD, progressive disease, and not evaluable)
c Durable SD is a subset of SD
d Excludes 5 of 7 patients in the FAS with progressive disease but no post-baseline tumor radiographic assessments
e Excludes 7 patients without post-baseline tumor assessments who are in the FAS
f Time to progression is defined as the time from the first date of enzalutamide treatment until the date of disease progression per RECIST v1.1
g Time to response is defined as the time from the first date of enzalutamide treatment to initial CR or PR
Efficacy end point Efficacy evaluable  seta (n = 89) Full analysis set (n = 96)
CBR24 (CR or PR or prolonged SD > 24 weeks), n [% (95% CI)] 21 [23.6 (15.2–33.8)] 21 [21.9 (14.1–31.5)]
Best overall response,b n (%)
 CR 0 (0) 0 (0)
 PR 4 (5) 4 (4)
 SD 42 (47) 42 (44)
  Durable SD at ≥ 24  weeksc 17 (19) 17 (18)
 Progressive disease 42 (47) 42 (44)d
 Not evaluable 1 (1) 1 (1)e
Best overall response rate (CR or PR), n [% (95% CI)] 4 [4.5 (1.2–11.1)] 4 [4.2 (1.1–10.3)]
Overall response rate at 24 weeks (CR or PR), n [% (95% CI)] 3 [3.4 (0.7–9.5)] 3 [3.1 (0.6–8.9)]
Time to progression (days),f median (95% CI) 108.0 (61–116) 108.0 (61–116)
Time to response (days),g median (range) 57.0 (57–222) 57.0 (57–222)
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Efficacy
In the primary efficacy analysis set, CBR24 was 24% 
(21/89 patients) (Table 2). Four (5%) patients had con-
firmed PR and 17 (19%) patients had durable SD at 
24  weeks. Additionally, 42 (47%) patients had a best 
overall response of SD. BORR was 5% and ORR at 
24 weeks was 3%. Median TTR and TTP were 57.0 days 
(range 57–222) and 108.0 days (95% CI 61–116), respec-
tively. Median PFS was 3.4 months (95% CI 2.0–3.8) 
(Fig. 1a). A plot of response to treatment for individual 
patients is shown in Fig. 1b.
Exploratory efficacy subgroup analyses
In exploratory analyses of efficacy in subgroups defined 
by AR-expression level (percentage of tumor cells with 
nuclear expression) and by HR status (HR + or HR−), 
CBR24 was similar in all subgroups versus the overall 
patient population (see Online Resource 6: Table S3). 
Additionally, efficacy did not appear to be affected by the 
number of previous lines of antineoplastic therapy or anti-
HER2 therapy (see Online Resource 7: Table S4).
Safety
Treatment-emergent adverse events (TEAEs) of any grade 
were reported in 97 (94%) patients; the most common 
(≥ 10%) included fatigue in 35 (34%) and nausea in 28 
(27%) patients (Table 3). Dyspnea (four patients = 4%) 
and malignant neoplasm progression due to breast cancer 
(three patients = 3%) were the only TEAEs of grade ≥ 3 
reported in ≥ 3 patients. Serious TEAEs were reported 
in 22 (21%) patients; the most frequent (≥ 2.0%) were 
malignant neoplasm progression due to breast cancer 
(five  patients = 5%), nausea (three  patients = 3%), and 
vomiting (three patients = 3%). Four patients (4%) expe-
rienced fatal TEAEs: (i) two malignant neoplasm pro-
gression, (ii) one pulmonary edema, and (iii) one general 
physical health deterioration associated with concurrent 
worsening abdominal pain and dyspnea. None of these 
fatal AEs were assessed as related to a study drug.
Enzalutamide- or trastuzumab-related TEAEs occurred 
in 78 (76%) patients (Table 3). Eight serious enzalutamide-
related TEAEs, nausea (two events), vomiting, diarrhea, 
dyspepsia, asthenia, accidental overdose, and dyspnea, 
were reported in three (3%) patients; no trastuzumab-
related serious TEAEs were reported. Drug-related TEAEs 
necessitating dose reduction of enzalutamide occurred in 
seven (7%) patients (see Online Resource 5: Table S2), the 
most frequent being fatigue (three patients = 3%). Study-
drug-related TEAEs led to permanent discontinuation of 
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Fig. 1  a Kaplan–Meier curve of progression-free  survivala in the full 
analysis set; b swimmer plot of response to treatment for individual 
patients aProgression-free survival is defined as the time from the 
date of first dose of enzalutamide until the date of disease progres-
sion per RECIST v1.1 or death from any cause on study (death within 
168  days after treatment discontinuation), whichever occurred first 
CI confidence interval, RECIST Response Evaluation Criteria in 
Solid Tumors
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Discussion
In this single-arm phase II study of enzalutamide plus 
trastuzumab in heavily pretreated patients with advanced 
HER2+ AR+ breast cancer, CBR24 was 24% in the primary 
analysis set, with a BORR of 5%. Overall, a median PFS of 
3.4 months was observed.
Direct comparisons cannot be made across differ-
ent clinical studies due to the heavily pretreated nature 
and specific AR+ subset of the HER2+ MBC patient 
population in this study, for which equivalent data are 
scarce. In a study with HER2+ locally advanced/MBC 
patients who had received a median of three trastuzumab 
regimens, lapatinib in combination with trastuzumab 
showed an ORR of 10.3% compared to 6.9% for lapatinib 
alone [6]. In the TH3RESA study of T-DM1 in patients 
who had previously received ≥ 2 HER2-directed regimens 
in the advanced setting, including trastuzumab and lapa-
tinib, median PFS (T-DM1 = 6.2 months versus physi-
cians’ choice = 3.3 months) was higher than in the current 
Table 3  Treatment-emergent 
adverse events
NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events, TEAE treat-
ment-emergent adverse event
a NCI CTCAE grade (v4.03)
b By preferred term
Event, n (%) Safety analysis 
set (n = 103)
Total number of TEAEs 97 (94)
Serious TEAEs 22 (21)
Enzalutamide- or trastuzumab-related TEAEs 78 (76)
Enzalutamide-related TEAEs 75 (73)
Trastuzumab-related TEAEs 39 (38)
Serious (enzalutamide-related) TEAEs 3 (3)
TEAE leading to permanent discontinuation of enzalutamide or trastuzumab 21 (20)
Study-drug-related TEAEs leading to permanent discontinuation of enzalutamide 5 (5)
Study-drug-related TEAEs leading to permanent discontinuation of trastuzumab 4 (4)
Deaths 4 (4)
Any grade TEAE (≥ 10% patients)a,b
 Fatigue 35 (34)
 Nausea 28 (27)
 Hot flush 17 (17)
 Decreased appetite 15 (15)
 Dyspnea 15 (15)






 Pain in extremity 11 (11)
 Vomiting 11 (11)
Grade ≥ 3 (≥ 2 patients)a,b
 Dyspnea 4 (4)
 Abdominal pain 2 (2)
 Back pain 2 (2)
 Fatigue 2 (2)
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study for T-DM1, although the patient populations are not 
directly comparable [20]. Overall, the combination of tras-
tuzumab plus enzalutamide appears to offer durable dis-
ease control in a subset of patients with heavily pretreated 
HER2+ AR+ MBC; however, the clinical impact of this 
observation is limited because those patients most likely 
to benefit could not be identified in advance.
The interpretation of these efficacy results should take 
into account the heavily pretreated patient population in 
this study (> 60% having received ≥ 3 previous lines of 
anti-HER2 therapy), although the number of previous lines 
of anti-HER2 therapy did not appear to be associated with 
CBR24. In this study, AR-expression levels and HR status 
did not appear to predict benefit of the combination. How-
ever, preclinical data suggest that AR plays a differential 
role in tumor suppression and oncogenesis within ER+ and 
ER− breast tissue, respectively [21]. The use of more 
sophisticated analyses of endocrine signaling may reveal the 
interaction of HR status and AR in HER2+ MBC in future 
trials. Current treatments for HER2+ MBC are based on 
anti-HER2 therapies [3, 4]; however, there remains a need 
for new targeted treatments with predictive biomarkers to 
identify patient subgroups that are most likely to respond, 
including patients with HER2+ AR+ MBC. Indeed, multi-
ple new treatments are being evaluated for HER2+ MBC, 
including cyclin D-dependent kinase 4/6 inhibitors, tyros-
ine kinase inhibitors, phosphoinositide 3-kinase inhibitors, 
mammalian target of rapamycin inhibitors, immunothera-
pies, antibody drug conjugates, monoclonal antibodies, and 
therapeutic dendritic cell-based vaccines [22, 23].
In this study, enzalutamide showed a favorable safety pro-
file, consistent with that seen in men with prostate cancer 
[17] and women with AR-expressing, triple-negative breast 
cancer [24]. No new safety signals were observed in this 
female breast cancer population. The frequencies of the most 
common enzalutamide-related TEAEs in this study, fatigue 
(30%) and nausea (20%), were in line with those reported in 
previous enzalutamide trials in men.
This study had limitations. It was a single-arm study 
consisting of a heterogenous population and, consequently, 
direct comparison of the efficacy and safety results of enza-
lutamide plus trastuzumab with other therapies is not pos-
sible. Moreover, information that may have assisted in the 
exploratory analyses to identify predictive biomarkers, such 
as further details of local genetic testing (e.g., HER2 gene 
copy number and fluorescence in situ hybridization ratio) 
and definitions of local estrogen receptor and/or proges-
terone receptor positivity, were not collected. Importantly, 
we were unable to centrally assess 24 locally reviewed 
AR+ cases and 11 HER2+ cases due to a lack of sample 
material.
Conclusions
The combination of enzalutamide and trastuzumab was well 
tolerated, and a subset of patients derived durable disease 
control. Determination of biomarkers to identify patients 
most likely to benefit from this combination are needed for 
this intervention to have a meaningful clinical impact.
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